LL-37
- Category
- Immune & Defense
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A natural cathelicidin antimicrobial peptide, marketed for infection, biofilms, and wound healing. Its antimicrobial and wound-healing effects are moderately supported and rest largely on lab and animal work, with thin human data and speculative anticancer claims. The main safety gap is cell toxicity at high doses (including red blood cell rupture) plus a self-DNA autoimmune link. Not an approved US drug, and unregulated products sold online are of uncertain purity.
Read Full recordStudied uses & evidence
Studied uses(6)
Broad-spectrum antimicrobial activity
MediumDisrupts membranes of many bacteria, fungi, and enveloped viruses in laboratory tests.
Anti-biofilm activity
LowPrevents and breaks up bacterial biofilms in lab studies, not yet tested in people.
Wound healing acceleration
MediumA human trial found topical use sped venous leg ulcer healing versus placebo.
Evidence limits
- Evidence Level
- Moderate
A 34-person venous-ulcer trial reported improved healing predictors, and a 25-person diabetic-foot-ulcer trial found improved granulation. A larger 148-person venous-ulcer trial found no significant overall healing benefit; favorable subgroup findings were exploratory. Phase I melanoma trial (NCT02225366) completed. A small exploratory study evaluated oral LL-37 for COVID-19. Most evidence remains preclinical, and the clinical wound-healing evidence is mixed.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Autoimmune conditions (psoriasis, lupus)
HighLL-37 is elevated in psoriatic lesions and may exacerbate autoimmune skin conditions. Forms DNA complexes that activate autoimmune pathways.
Rosacea
ModerateLL-37 is pathogenically elevated in rosacea. Exogenous administration may worsen the condition.
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
At high concentrations LL-37 can damage human cells including red blood cells (hemolysis)
ModerateLL-37 is rapidly broken down by proteases, limiting half-life
ModerateLL-37 complexed with self-DNA can activate plasmacytoid dendritic cells (autoimmunity link)
ModerateBacteria can develop resistance to LL-37 through membrane modifications
ModerateLL-37 antimicrobial activity diminished by serum, salt, and divalent cations
HighThe melanoma trial (NCT02225366) noted dermatologic toxicity at intratumoral injection sites
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.